Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals develops therapeutics with small molecule lipid mediators for the treatment of inflammatory diseases. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
$125m (Public information from Nov 2010)
Cambridge Massachusetts (HQ)
  • Edit
DateInvestorsAmountRound

$17.0m

Series A
*

$25.0m

Series B
N/A

$1.2m

Debt
N/A

$2.5m

Valuation: $125m

Late VC
Total Funding$44.5m

Recent News about Resolvyx Pharmaceuticals

Edit
More about Resolvyx Pharmaceuticalsinfo icon
Edit

Resolvyx Pharmaceuticals focuses on developing innovative therapies that target inflammation and immune responses to treat chronic diseases. The company operates in the biopharmaceutical sector, aiming to address unmet medical needs in conditions such as asthma, cardiovascular diseases, and neurodegenerative disorders. Resolvyx's business model revolves around research and development, leveraging proprietary technology to create novel drug candidates. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The primary clients include healthcare providers, pharmaceutical companies, and research institutions. The market is highly competitive, with a strong emphasis on scientific innovation and regulatory compliance.

Keywords: biopharmaceutical, inflammation, immune response, chronic diseases, asthma, cardiovascular, neurodegenerative, research, development, innovation.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.